Alkermes Q2 Sales Up 14 Percent

Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus Wall Street expectations, with diluted earnings per share (GAAP) coming in at $0.52, well above the GAAP consensus estimate of $0.36. Revenue (GAAP) also surprised to the upside at $390.7 million, exceeding the $341.4 million GAAP analyst estimate, though down 2.1% compared to Q2 2024. Proprietary drugs for central nervous system disorders drove 14% year-over-year growth, helping offset marked declines in legacy manufacturing and royalty streams. Overall, the quarter showed strong financial discipline, continued pipeline investment, and heavy reliance on the performance of Alkermes' key marketed neuroscience products. Source: Analyst estimates for the quarter provided by FactSet. Alkermes is a pharmaceuticals company specializing in proprietary medicines that address central nervous system (CNS) disorders such as schizophrenia, bipolar disorder, alcohol dependence, and opioid dependence. Its U.S.-marketed portfolio includes ARISTADA, a long-acting injectable antipsychotic for schizophrenia; LYBALVI, an oral medication approved for schizophrenia and bipolar I disorder; and VIVITROL, an extended-release injectable for alcohol and opioid dependence.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool